Navigation Links
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
Date:1/7/2008

disorder that causes exceptionally high levels of LDL-cholesterol. After appropriate clinical development, the next indication pursued for mipomersen will be for other patients with high cholesterol at high risk of cardiovascular events.

Deal Terms

Isis will transition development responsibility for mipomersen to Genzyme over the next two years. In addition to the up-front payment, Isis also has the opportunity to receive from Genzyme up to $825 million in development and regulatory milestone payments plus up to $750 million in commercial milestone payments.

Genzyme and Isis will share mipomersen profits 50/50 when annual worldwide revenues reach $2 billion or more. The profit share begins with a 70/30 Genzyme/Isis split and reaches 50/50 on a sliding scale as annual revenues ramp up to $2 billion.

"Genzyme is reconfirming its 2008 and five-year earnings guidance, and we will manage the financial impact of this agreement within our previously stated goal of 20 percent compound annual growth in non-GAAP earnings per share through 2011," noted Mr. Termeer.

"We believe the profit sharing transaction we have structured with Genzyme is uniquely beneficial to Isis," added Dr. Crooke. "It allows us to benefit in the short term and over time through up-front licensing fees and milestones, while retaining substantial economic participation in the commercialization of the drug. We look forward to working with Genzyme on mipomersen as well as potentially on drugs for CNS and certain rare diseases."

Closure of the transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act.

About Familial Hypercholesterolemia (FH)

FH patients have high blood concentrations of LDL-cholesterol due to a genetic disorder which prevents proper metabolism of LDL-cholesterol. These patients experience a markedly increased risk of premature cardiovascular diseases (CVD) and CVD-related death. Familial hypercholestero
'/>"/>

SOURCE Genzyme Corp.; Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
2. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
3. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
4. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
5. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
6. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
7. Genzyme Launches Cholestagel(R) in Europe
8. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
9. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
10. Genzyme Recognized by Scientists as a Top Employer
11. Genzyme Receives Approval to Market Elaprase(R) in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... , June 2, 2015 ... global antibiotic resistance problem  MGB Biopharma, ... of anti-infectives, to address the major global problem ... developed a stable intravenous (IV) formulation of MGB-BP-3, designed ... Gram-positive hospital-acquired infections.  The intravenous formulation of ...
(Date:6/2/2015)... LA (PRWEB) June 02, 2015 ... gene synthesis to improve protein expression, announced the formation ... includes six executives and entrepreneurs with a broad range ... industries. , The team includes: , Jimmy Roussel, ... , Roussel has a background in technology and marketing. ...
(Date:6/1/2015)...  Turing Pharmaceuticals AG announced that life sciences executive ... MSc,  has joined the company as president of ... holds a medical degree as well as a ... accomplishments in the pharmaceutical industry, and extensive clinical ... played a leadership role in numerous programs for ...
(Date:6/1/2015)... MONTREAL and YONGIN, South Korea ... with great pride that Green Cross Biotherapeutics Inc. (GCBT) ... will be located on the Montreal Technoparc,s Saint-Laurent Campus. ... green field investment projects in Canada ... construction of the first intravenous immunoglobulin (IVIG) and albumin ...
Breaking Biology Technology:MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3
... CHENGDU, China , June 3 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., Inc. (NYSE ... the updated corporate presentation at the Company,s website: , , ... http://www.tianyinpharma.com , , , ... , , ...
... June 2 Caliper Life Sciences, Inc. (Nasdaq: CALP ... Sciences Conference, will be webcast on Friday, June 11 at ... will be providing an update on the company,s business. The live webcast ... available for 90 days. , , ...
... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that Kevin ... at the Jefferies 2010 Global Life Sciences Conference and also at the 9th ... , , ... place on Wednesday, June 9, 2010 at 1:30 p.m. Eastern ...
Cached Biology Technology:Tianyin Corporate Presentation Updated 2Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference 2
(Date:5/21/2015)... May 21, 2015 The Sync Project™ ... music for health, today announced a collaborative partnership with ... partnership will center on collaboration on original research, joint ... step in the collaboration, The Sync Project and BerkleeICE ... as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
(Date:5/11/2015)... 11, 2015  Through a well-rounded UAS delegation representing private ... a strong showing at AUVSI,s Unmanned 2015 conference last week ... Ohio,s UAS industry met with over 200 ... points along the UAS ecosystem. "Our message ... President for Aerospace Rich Knoll . "If you want ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... A research paper co-written by a Virginia Tech faculty ... nose that is unusually large for its species. The ... journal, Physical Review Letters . The article, ... morphology," by Z. Zhang, R. Mller, and S.N. Truong, ...
... have a clear agenda when it comes to selecting a ... and preferring large females, they are likely to have more ... Beat Mattle and Tony Wilson from the Zoological Museum at ... have just been published online in Springer,s journal Behavioral ...
... of Interventional Radiology 2009 Standards Division Guidelines" is ... July issue of the Journal of Vascular ... physicians, scientists and allied health professionals dedicated to ... invasive, image-guided therapeutic interventionsprovides a unique collection of ...
Cached Biology News:Mystery of bat with an extraordinary nose solved 2Male seahorses like big mates 2Journal of Vascular and Interventional Radiology: New patient radiation safety guidelines 2Journal of Vascular and Interventional Radiology: New patient radiation safety guidelines 3
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
... Kit is manufactured for DNA purification from ... to UV light. The Purification of DNA ... for DNA-cloning work. The conventional method of ... of UV light damages DNA and significantly ...
... antibody raised against a partial recombinant MAK. ... ~ 457 a.a) partial recombinant protein with GST ... Accession: BC039825 ... OMIM: 154235, GeneID: ...
Mouse monoclonal antibody raised against a partial recombinant L3MBTL2. NCBI Entrez Gene ID = L3MBTL2...
Biology Products: